Balkrishna Industries (502355) Q2 26/27 earnings summary

Executive summary

• Q2FY27 standalone total income rose 49% YoY to ₹3,450 crore; EBITDA increased 26% to ₹629 crore, while net profit grew 10% to ₹291 crore.

• H1FY27 standalone total income grew 35% to ₹6,859 crore and net profit rose 31% to ₹723 crore; margin pressure reflected raw-material inflation and freight costs.

• Vision 2030 targets growth across OHT, on-road tires and Carbon Black, including a ₹23,000 crore FY30 revenue target and expansion into premium PCR tires through the Pirelli partnership.

Financial highlights

• Q2FY27 standalone total income was ₹3,450 crore versus ₹2,320 crore; EBITDA was ₹629 crore versus ₹500 crore, and PBT was ₹388 crore versus ₹347 crore.

• Q2FY27 standalone net profit was ₹291 crore versus ₹265 crore; H1FY27 net profit was ₹723 crore versus ₹552 crore.

• H1FY27 standalone total income was ₹6,859 crore versus ₹5,079 crore; EBITDA was ₹1,332 crore versus ₹1,155 crore, and PBT was ₹970 crore versus ₹738 crore.

• Q2 consolidated revenue was ₹3,471.74 crore and net profit ₹292.62 crore; H1 consolidated revenue was ₹6,927.01 crore and net profit ₹743.39 crore.

• H1FY27 tire sales volume was 185,167 MT, up 23% YoY; Q2 volume was 91,397 MT, up 30%.

Outlook and guidance

• FY30 revenue target is ₹23,000 crore, 2.2x the ~₹10,600 crore 2025 base, implying a ~17% five-year CAGR; target revenue mix is OHT ~70%, on-road ~20% and Carbon Black ~10%.

• FY30 targets include 8% global OHT market share, 5% on-road market share and 20% of turnover from the on-road vertical.

• CapEx through FY29 is planned at ₹6,800 crore; OHT capacity is expected to reach 425,000 MTPA through 35,000 MTPA of CapEx and debottlenecking.

• Management aims to sustain the recent volume run rate without confirming a quarterly target; raw-material and freight headwinds are expected to continue, with a tactical balance between pricing and volume.

• Blended margins are expected at 23%-25% after full commercialization; long-term EBITDA margin ambition is 20%-25%. PCR pilot is planned for January 2027, with gradual ramp-up.